U.S. Household Products Stock News

What Coupang’s Q1 2026 earnings mean for investors Coupang (CPNG) reported Q1 2026 revenue of US$8,504 million and a net loss of US$266 million, a shift from profit a year earlier. This result puts the tradeoff between growth and profitability in focus. See our latest analysis for Coupang. Coupang’s recent Q1 result, together with its US$84 million commitment to AI startups and robotics partnerships, comes after a 9.55% 1 month share price return but a year to date share price return of...

Corebridge Financial (CRBG) opened 2026 earnings season with Q1 results that sit against a recent backdrop where Q4 2025 revenue was about US$6.6b, basic EPS came in at US$1.59, and trailing twelve month EPS was a US$0.68 loss on revenue of roughly US$18.6b. Over the past few quarters, revenue has moved between US$3.2b and US$6.6b while quarterly basic EPS has swung from a loss of US$1.20 to a profit of US$3.81. This underlines how volatile the earnings line has been. For investors, the...

Why MKS Stock Is On Investors’ Radar MKS (MKSI) has been drawing attention after a strong run over the past year, with the stock’s recent price of $287.65 sitting against a backdrop of multi segment semiconductor exposure. See our latest analysis for MKS. The recent pullback in the share price over the last day contrasts with a strong run, with a 30 day share price return of 22.6% and a 1 year total shareholder return of very close to 300%. This suggests that momentum has been building rather...

AdaptHealth (AHCO) has just posted its latest results with Q4 2025 revenue of US$846.3 million and a basic EPS loss of US$0.74, setting the tone for how investors will read the Q1 2026 update. The company has seen quarterly revenue move from US$856.6 million in Q4 2024 to US$846.3 million in Q4 2025, while EPS shifted from US$0.34 to a loss of US$0.74 over the same period. This puts the focus squarely on earnings quality. With the stock trading at US$11.75, investors may pay close attention...

IBM (NYSE:IBM) used its Think 2026 conference to unveil a broad set of enterprise AI and cloud management tools aimed at large organizations. The company introduced IBM Sovereign Core, targeting operational sovereignty and controls for regulated and data sensitive clients. IBM highlighted quantum simulation work with Cleveland Clinic on large protein complexes, focused on biopharma and applied science use cases. The company also announced an expanded industrial AI alliance with Aramco,...

If you are wondering whether Catalyst Pharmaceuticals' recent share price puts it at a bargain or a stretch, the following sections break that question down into clear valuation checks. The stock last closed at US$30.86, with returns of 4.8% over the past week, 25.0% over the past month, 33.3% year to date and 33.8% over the past year, which raises questions about how that performance lines up with underlying value. Recent headlines around Catalyst Pharmaceuticals have focused on its...

Grab Holdings (NasdaqGS:GRAB) has agreed to acquire Delivery Hero’s foodpanda business in Taiwan, marking its first major move beyond Southeast Asia. The deal extends Grab’s delivery footprint into a new market where it has not previously operated. Indonesia has introduced a new regulatory cap on ride hailing commissions, cutting the maximum rate from 20% to 8% and adding new social protections for drivers. These regulatory changes directly affect Grab’s largest regional market and could...

If you are wondering whether BlackSky Technology's current share price reflects its true worth, the recent performance gives plenty to think about. The stock last closed at US$35.96, with returns of 15.2% over 7 days, 16.7% over 30 days, 72.7% year to date, 321.1% over 1 year and 284.2% over 3 years, while the 5 year return sits at a 54.6% decline. Recent price action has drawn attention to BlackSky Technology, with investors focusing on how current expectations align with the stock's past...

Douglas Dynamics (PLOW) opened 2026 with Q1 results that follow a busy 2025, where quarterly revenue ranged from US$115.1 million to US$194.3 million and basic EPS moved between almost flat at US$0.01 and a peak of about US$1.10. Over that period, the company has seen revenue step up from US$143.5 million in Q4 2024 to US$184.5 million in Q4 2025, while basic EPS shifted from US$0.33 to US$0.54, framing a mixed but data rich set of trends for investors to weigh as they assess how margins are...

Danaher (NYSE:DHR) has launched a multi billion euro debt offering. The company plans to use the proceeds primarily to finance its acquisition of Masimo Corporation. The transaction is expected to affect Danaher's capital structure and business mix once completed. Danaher operates across life sciences and diagnostics, so adding Masimo's patient monitoring and medical technology portfolio would further extend its healthcare reach. For investors, the size and currency of the euro debt raise...

BioMarin Pharmaceutical (BMRN) opened 2026 with Q1 results that build on a run of quarterly revenue between US$745.1 million and US$874.6 million over 2025, while EPS has swung from a profit of US$1.25 in Q2 2025 to a loss of US$0.24 in Q4 2025 as one off items fed into the reported figures. Over the last six reported quarters, revenue has ranged from about US$745.1 million to US$874.6 million and trailing 12 month EPS has moved between US$1.70 and US$3.44. This gives you a clear view of how...

Why Cloudflare stock is back in focus Cloudflare (NET) is drawing fresh attention after an independent research firm named it a Leader in edge development platforms, highlighting its vision, roadmap and AI application development capabilities. The company also rolled out Flagship, a feature flag service built into its global edge platform that is designed to support AI generated code patterns. For investors, both developments add context to recent enthusiasm around Cloudflare's role in AI...

Axsome Therapeutics (AXSM) Q1 2026 earnings snapshot Axsome Therapeutics (AXSM) has opened 2026 with Q1 revenue of US$191.2 million and a basic EPS loss of US$1.26, alongside a net loss of US$64.5 million, setting a clear benchmark for how the rest of the year might look. The company has seen revenue progress from US$118.8 million in Q4 2024 to US$191.2 million in Q1 2026, while trailing twelve month EPS has moved from a loss of US$5.99 to a loss of US$3.74 as revenue reached US$708.2 million...

Market snapshot and recent returns Solventum (SOLV) has drawn fresh attention after a period of mixed share performance, with a 2.4% move over the past day and a month gain of 8.6% contrasting with a 9.7% decline over the past 3 months. At a last close of $69.04, the company has a value score of 5 and a market cap of about $11.7b. This has invited closer scrutiny of how its healthcare operations and recent results line up with current pricing. See our latest analysis for Solventum. For...

Event context and recent performance Chefs' Warehouse (CHEF) has attracted attention after recent share price moves, with the stock showing a 1 day return of 1.3%, about 23% over the past week, and around 37% over the past month. See our latest analysis for Chefs' Warehouse. Chefs' Warehouse's recent 1 month share price return of 37.22% sits within a broader upswing, with a year to date share price return of 26.66% and a 1 year total shareholder return of 29.34%, pointing to momentum that has...

Ameresco Q1 2026 earnings in focus Ameresco (AMRC) has come into Q1 2026 with recent quarterly figures that show Q4 2025 revenue at US$581.0 million and basic EPS of US$0.35, alongside trailing twelve month revenue of about US$1.9 billion and basic EPS of US$0.84. The company has seen quarterly revenue move from US$500.9 million in Q3 2024 to US$581.0 million in Q4 2025, while basic EPS over those reported quarters ranged from US$0.24 to US$0.71. This sets up the latest update against a...

In recent days, Tyra Biosciences reported interim Phase 1/2 data for its lead candidate TYRA-300 in metastatic urothelial carcinoma, showing an objective response rate alongside a favorable safety profile. At the same time, the company advanced its bladder cancer pipeline through a new SURF302 trial partnership with the University of Kansas Medical Center, highlighting external confidence in its FGFR3-focused approach. Next, we will examine how TYRA-300’s interim efficacy signal shapes...

Waters (WAT) has just wrapped up its Q1 2026 earnings season backdrop with a recent run of quarterly results that saw Q4 2025 revenue at US$932.4 million and basic EPS of US$3.78, compared with US$872.7 million of revenue and basic EPS of US$3.90 in Q4 2024. Over the past few quarters, revenue has moved from US$740.3 million in Q3 2024 to US$799.9 million in Q3 2025 and US$932.4 million in Q4 2025. Basic EPS has shifted from US$2.72 to US$2.50 and then US$3.78, setting up a results season...

Viridian Therapeutics (VRDN) Q1 2026 Earnings Snapshot Viridian Therapeutics (VRDN) has followed up its Q1 2026 update by showing investors a recent run of small reported revenues against sizeable losses, with Q4 2025 revenue at US$0.132 million, basic EPS at a loss of US$1.07 and net income loss of US$101.1 million setting the latest reference point. Over recent quarters the company has seen revenue move between US$0.072 million and US$70.57 million, while basic EPS has ranged from a loss of...

Wondering if BeOne Medicines at around US$297.49 is still offering value after a strong run? This article focuses squarely on what that price might really represent. The stock has returned 23.1% over the past year. The shorter term picture shows a 0.2% slip over 7 days, 4.3% over 30 days and 4.4% year to date. Recent news around BeOne Medicines has kept attention on the stock, with investors weighing how company developments align with its current share price. These headlines help frame...

If you are asking whether Fiserv at around US$57.28 is a bargain or a value trap, you will want to understand what the current valuation signals are really saying. The stock has seen a 7% decline over the last 7 days, a 2% gain over the last 30 days, a 12.7% decline year to date, and a 69% decline over the last year, which can change how the market prices its potential and its risks. Recent commentary around Fiserv has focused on its position within diversified financial services and how it...

Wondering if Match Group at around US$37.65 is offering value or just noise? This article breaks down what the current price might be implying about the stock. The stock has returned 1.7% over the last 7 days, 19.8% over the last 30 days, 18.6% year to date and 28.7% over the last year, while the 5 year return sits at a 73.4% decline. These moves come as investors continue to reassess online dating platforms and subscription based business models. Match Group is often in focus during broader...

Adeia (ADEA) sets the tone with Q1 2026 results Adeia (ADEA) opened Q1 2026 with trailing 12 month revenue of US$443.4 million and basic EPS of US$1.02, following a recent quarter where it booked US$182.6 million in revenue and basic EPS of US$0.68. Over the past year, revenue has moved from US$376.0 million to US$443.4 million on a trailing basis, while trailing basic EPS shifted from US$0.59 to US$1.02, giving investors a clearer view of how topline and per share earnings have tracked ahead...

Wondering whether Nucor at around US$232 per share is offering value or stretching expectations? This article focuses squarely on what the current price may imply. The stock has returned 3.1% over the last 7 days, 34.6% over the last 30 days, 37.0% year to date and 101.6% over the last year, which naturally raises questions about how much future potential is already reflected in the price. Recent coverage of steel producers and materials suppliers has highlighted how investor attention often...